Please use this identifier to cite or link to this item: http://hdl.handle.net/10201/36001

Title: Focal adhesion kinase and cancer
Issue Date: 2009
Publisher: Murcia : F. Hernández
ISSN: 0213-3911
Related subjects: 616 - Patología. Medicina clínica. Oncología
Keywords: Focal adhesion kinase
Cancer
Abstract: Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that resides at the sites of integrin clustering, known as focal adhesions. The FAK protein has a molecular mass of 125kDa and is encoded by the FAK gene located on human chromosome 8q24. Structurally, FAK consists of an amino-terminal regulatory FERM domain, a central catalytic kinase domain, two proline-rich motifs, and a carboxy-terminal focal adhesion targeting domain. FAK has been shown to be an important mediator of cell growth, cell proliferation, cell survival and cell migration, all of which are often dysfunctional in cancer cells. Our lab was the first to isolate FAK from primary human tissue and link it to the process of tumorigenesis. We analyzed FAK mRNA expression in normal, invasive and metastatic human tissues and demonstrated through Northern blot analysis that normal tissues had very low levels of FAK mRNA while primary and metastatic tumors significantly overexpressed FAK. We also demonstrated and confirmed FAK overexpression in colorectal carcinoma and liver metastases with real-time PCR. In this review we summarized immunohistochemical data of FAK expression and role in different cancer types tumors and discussed FAK inhibition therapy approaches.
Primary author: Golubovskaya1, Vita M.
Kweh, Frederick A.
Cance, William G.
Published in: Histology and histopathology
URI: http://hdl.handle.net/10201/36001
Document type: info:eu-repo/semantics/article
Number of pages / Extensions: 8
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Vol.24, nº4 (2009)

Files in This Item:
File Description SizeFormat 
Focal adhesion kinase and cancer.pdf459,46 kBAdobe PDFThumbnail
View/Open


Items in Digitum are protected by copyright, with all rights reserved, unless otherwise indicated.